| Document Date: 2014-11-03 11:26:23
Open Document File Size: 158,07 KBShare Result on Facebook
City Osaka / / Company Shionogi Inc. / Shionogi & Co. Ltd. / Japan Shionogi & Co. / IMMEDIATE RELEASE SHIONOGI INC. / / Event FDA Phase / / IndustryTerm pharmaceutical / Healthcare providers / / MedicalCondition Cerebral palsy / cancer / palsy / flushing / neurological disorders / nausea / nasal congestion / skin irritation / allergy / Metabolic Syndrome / pain / intestinal pseudo-obstruction / excessive drooling / vomiting / Infectious Diseases / diarrhea / constipation / mechanical intestinal obstruction / chronic severe drooling / / Organization U.S. Food and Drug Administration / FDA / / Person Donald C. Manning / / / Position Chief Medical Officer / / Product potassium chloride / pseudo / Haloperidol / glycopyrrolate / Digoxin / Crestor / Atenolol / CUVPOSA™ (glycopyrrolate) / / URL www.shionogi.co.jp / www.fda.gov/medwatch / www.shionogi-inc.com / /
SocialTag |
Microsoft Word - GlycoFDAApprovalPressRelease72910.doc